Innate Pharma (NASDAQ:IPHA) Shares Up 1.9% – What’s Next?

Shares of Innate Pharma S.A. (NASDAQ:IPHA) shot up 1.9% during mid-day trading on Friday . The stock traded as high as $2.16 and last traded at $2.13. 10,035 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 325,721 shares. The stock had previously closed at $2.09.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $11.50 price target on shares of Innate Pharma in a research report on Thursday, February 6th.

Innate Pharma Price Performance

The stock has a 50 day moving average of $1.93 and a 200 day moving average of $1.97.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.